Atai Life Sciences N.V. Statistics
Share Statistics
Atai Life Sciences N.V. has 167.80M shares outstanding. The number of shares has increased by 1.08% in one year.
| Shares Outstanding | 167.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 117.06M |
| Failed to Deliver (FTD) Shares | 672 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 10.61M, so 6.32% of the outstanding shares have been sold short.
| Short Interest | 10.61M |
| Short % of Shares Out | 6.32% |
| Short % of Float | 9.06% |
| Short Ratio (days to cover) | 5.49 |
Valuation Ratios
The PE ratio is -5.57 and the forward PE ratio is -2.15.
| PE Ratio | -5.57 |
| Forward PE | -2.15 |
| PS Ratio | 713.23 |
| Forward PS | 595 |
| PB Ratio | 0.92 |
| P/FCF Ratio | -2.64 |
| PEG Ratio | n/a |
Enterprise Valuation
Atai Life Sciences N.V. has an Enterprise Value (EV) of 195.40M.
| EV / Earnings | -4.86 |
| EV / Sales | 622.29 |
| EV / EBITDA | -5.38 |
| EV / EBIT | -1.56 |
| EV / FCF | -2.31 |
Financial Position
The company has a current ratio of 9.22, with a Debt / Equity ratio of 0.08.
| Current Ratio | 9.22 |
| Quick Ratio | 9.22 |
| Debt / Equity | 0.08 |
| Total Debt / Capitalization | 7.3 |
| Cash Flow / Debt | -4.39 |
| Interest Coverage | -47.24 |
Financial Efficiency
Return on equity (ROE) is -0.17% and return on capital (ROIC) is -48.86%.
| Return on Equity (ROE) | -0.17% |
| Return on Assets (ROA) | -0.14% |
| Return on Capital (ROIC) | -48.86% |
| Revenue Per Employee | 3.78K |
| Profits Per Employee | -484.63K |
| Employee Count | 83 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 1.02M |
| Effective Tax Rate | -0.03 |
Stock Price Statistics
The stock price has increased by -28.49% in the last 52 weeks. The beta is 0.78, so Atai Life Sciences N.V.'s price volatility has been higher than the market average.
| Beta | 0.78 |
| 52-Week Price Change | -28.49% |
| 50-Day Moving Average | 1.45 |
| 200-Day Moving Average | 1.49 |
| Relative Strength Index (RSI) | 43.33 |
| Average Volume (20 Days) | 1.71M |
Income Statement
In the last 12 months, Atai Life Sciences N.V. had revenue of 314.00K and earned -40.22M in profits. Earnings per share was -0.25.
| Revenue | 314.00K |
| Gross Profit | 314.00K |
| Operating Income | -125.47M |
| Net Income | -40.22M |
| EBITDA | -36.31M |
| EBIT | -125.47M |
| Earnings Per Share (EPS) | -0.25 |
Balance Sheet
The company has 45.03M in cash and 19.14M in debt, giving a net cash position of 25.89M.
| Cash & Cash Equivalents | 45.03M |
| Total Debt | 19.14M |
| Net Cash | 25.89M |
| Retained Earnings | -550.94M |
| Total Assets | 197.52M |
| Working Capital | 94.43M |
Cash Flow
In the last 12 months, operating cash flow was -84.12M and capital expenditures -590.00K, giving a free cash flow of -84.71M.
| Operating Cash Flow | -84.12M |
| Capital Expenditures | -590.00K |
| Free Cash Flow | -84.71M |
| FCF Per Share | -0.53 |
Margins
Gross margin is 100%, with operating and profit margins of -39.96K% and -12.81K%.
| Gross Margin | 100% |
| Operating Margin | -39.96K% |
| Pretax Margin | -12.51K% |
| Profit Margin | -12.81K% |
| EBITDA Margin | -11.56K% |
| EBIT Margin | -39.96K% |
| FCF Margin | -26.98K% |
Dividends & Yields
ATAI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -18.8% |
| FCF Yield | -37.96% |
Analyst Forecast
The average price target for ATAI is $10, which is 651.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 651.9% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -2.7 |
| Piotroski F-Score | 3 |